SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid's stock is trending downwards, with the community expressing concerns about the company's financial future and comparing it unfavorably to competitors like Tesla and Rivian. Recent news of price cuts on existing models and a cheaper Gravity SUV trim has some worried about potential margin impacts, while others question the company's leadership and strategy. Despite some positive sentiment regarding Lucid's technology, overall sentiment appears quite negative.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

Fly-E Group is trending due to high volatility and speculation of a potential short squeeze, evidenced by a massive increase in trading volume. The community is actively discussing dark pool short interest and debating whether the stock can repeat the dramatic moves of similar plays, while others warn of the risks associated with pump-and-dump schemes and the company's fundamentals.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending after crushing earnings expectations, with revenue and EPS significantly exceeding estimates, leading to bullish sentiment and analysts raising price targets. The community is discussing the stock's potential for continued growth in the AI space and comparing it to competitors like Oracle. Some traders caution about valuation and potential pullbacks, while others highlight the stock's strength and potential for further gains.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is trending due to upcoming data presentations at the ASH conference, particularly for its IRAK1/4 inhibitor R289, with potential implications for the lucrative MDS market. Community discussions revolve around buyout potential, low P/E ratio, and speculation about short positions ahead of these events. Bullish sentiment is fueled by institutional ownership and revenue growth, while some traders eye options and potential short squeezes.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amid discussions about its valuation, pipeline, and recent acquisition of Astria Therapeutics, with the community debating short interest and potential catalysts. Investor sentiment appears mixed, with some expressing frustration over the stock's performance, while others highlight its revenue growth and potential in the HAE market. A key upcoming event is the FDA decision on Orladeyo for pediatric use.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

ARWR is trending following positive analyst sentiment and community excitement surrounding its RNAi platform and deep pipeline, especially after a recent deal with Novartis. Discussions highlight the potential for multiple upcoming catalysts, including data readouts and a PDUFA date, to significantly increase the company's valuation. Some investors believe ARWR may outperform its peers.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Panda ($PANDU) is gaining traction, with community members highlighting its strong community, consistent development, and potential utility within the Solana ecosystem. Discussions revolve around its low market cap relative to potential upside, branding, and upcoming announcements, leading to increased attention and trending status.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot ($HD) is trending amid discussions around potential benefits from future Fed rate cuts and its strategic positioning in the home improvement sector. Community members are analyzing technical indicators and potential price movements, with some pointing to oversold conditions and potential bounce opportunities. Some analysts have updated their ratings on the stock, while others debate the impact of tariffs and housing market trends on $HD's performance.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

CSCO is trending due to its potential to capitalize on the growing AI infrastructure market and recent partnerships, with community members drawing comparisons to its role during the dot-com era. Discussions revolve around the company's AI networking solutions and potential for revenue growth, as well as debate about whether it can reach new all-time highs. Option traders are actively trading calls, suggesting bullish sentiment, while others express concerns about valuation and potential pullback.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology (MRVL) is trending amid discussions around its AI prospects and potential acquisitions, with community members weighing in on upcoming earnings and future price movement. Recent news of a potential acquisition of Celestial AI is circulating, as well as speculation around a SoftBank takeover that could merge MRVL with ARM. Bullish sentiment remains, with many anticipating a rise to $100+ following earnings and continued expansion in the AI sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYDY BULLISH!!! HAVE A GREAT WEEKEND LONGS!!! EXCITING TIMES AHEAD!!! HEAR IS PART 1 OF DR. JAY&#39;S LATEST INTERVIEW!!! REST OF IT WILL BE IN MY COMMENTS!!! ALL IN TO WIN!!! ALL IN TO SAVE LIVES!!!  
Guest today is Dr. Jay Lalezari, CEO of CytoDyn, cytodyn.com. And Jay, I want to 
welcome you to the show. I appreciate you taking a few minutes to be with us. 
Jay Lalezari: Thank you, Karen. It&#39;s a pleasure to join you. 
Karen Jagoda: Thank you. We wanted to talk today about triple-negative breast cancer. So tell 
us why the company has decided to focus on that condition. Jay Lalezari: When I became CEO back in November of 2023, my first order of business was 
to figure out where CytoDyn should go with this intriguing monoclonal antibody 
called leronlimab that targets CCR5. And we looked at a number of indications, 
and by far and away, the data that we found in solid tumor oncology is clearly 
the place CytoDyn will go to create the most benefit for patients.....

Todd Langevin

Brian

CJ Sigler

Tuna T

Thomas Migliara

Rich F

Robert

Stuttgart Mercedes

Thor

Maggie16

Doug Chase

dd :)

Scott Bowers

Thomas H Butcher

Tom Wright

Joe Blow

Derek White

S. T.

anh vo

Paul Steele

Dustin

Ryan Morrison

vivamiga

Scott

christopher

Timothy OConnor

Gailgooglie

Charles

CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications based on Leronlimab (PRO 140).

CytoDyn Inc.

StockTwits Web

CytoDyn Inc

 BULLISH!!! HAVE A GREAT WEEKEND LONGS!!! EXCITING TIMES AHEAD!!! HEAR IS PART 1 OF DR. JAY'S LATEST INTERVIEW!!! REST OF IT WILL BE IN MY COMMENTS!!! ALL IN TO WIN!!! ALL IN TO SAVE LIVES!!!  
Guest today is Dr. Jay Lalezari, CEO of CytoDyn, 

. And Jay, I want to 
welcome you to the show. I appreciate you taking a few minutes to be with us. 
Jay Lalezari: Thank you, Karen. It's a pleasure to join you. 
Karen Jagoda: Thank you. We wanted to talk today about triple-negative breast cancer. So tell 
us why the company has decided to focus on that condition. Jay Lalezari: When I became CEO back in November of 2023, my first order of business was 
to figure out where CytoDyn should go with this intriguing monoclonal antibody 
called leronlimab that targets CCR5. And we looked at a number of indications, 
and by far and away, the data that we found in solid tumor oncology is clearly 
the place CytoDyn will go to create the most benefit for patients.....

Steven feldman

$CYDY BULLISH PART 2 and the most 
benefit for our shareholders. We recently presented some data in triple- 
negative breast cancer that is truly remarkable and potentially paradigm-shifting 
in the world of solid tumor oncology. 
Karen Jagoda: So, say more about what you mean by paradigm shifting, because solid tumors 
have been attacked fairly successfully, but you&#39;re taking it to the next level. 
Jay Lalezari: Yeah. There are a number of solid tumors, triple negative breast cancer among 
them, where we still struggle to find effective therapies, in part because, by 
virtue of being triple negative, there aren&#39;t a lot of good targets on the cancer. 
And some years ago, CytoDyn launched three clinical studies in oncology 
focusing on women with triple-negative breast cancer. And those studies ran for 
a couple of years, they were then shut down, and there was a period of time 
where patients were lost to follow-up.

 BULLISH PART 2 and the most 
benefit for our shareholders. We recently presented some data in triple- 
negative breast cancer that is truly remarkable and potentially paradigm-shifting 
in the world of solid tumor oncology. 
Karen Jagoda: So, say more about what you mean by paradigm shifting, because solid tumors 
have been attacked fairly successfully, but you're taking it to the next level. 
Jay Lalezari: Yeah. There are a number of solid tumors, triple negative breast cancer among 
them, where we still struggle to find effective therapies, in part because, by 
virtue of being triple negative, there aren't a lot of good targets on the cancer. 
And some years ago, CytoDyn launched three clinical studies in oncology 
focusing on women with triple-negative breast cancer. And those studies ran for 
a couple of years, they were then shut down, and there was a period of time 
where patients were lost to follow-up.

$CYDY BULLISH!!! PART 3 Jay Lalezari: We have now been able to follow up on the 28 women who were enrolled in 
that study and have found that five of them are alive today, about five plus 
years later, three of whom have no evidence of disease. And these are women 
who were fourth-line median, fourth-line treatment median of two previous 
lines of treatment in the metastatic setting. 60% had organ metastasis, 30% had 
brain metastasis. The median survival of a population like that is generally 
measured in weeks or months. And the fact that we have five out of 28 who are 
alive and doing well in what appears to be a sustained remission five years later 
is absolutely remarkable. It is retrospective, but it is remarkable nonetheless. 
Karen Jagoda: Tell us a little bit about the CCR5 receptor, which is part of this story, and why 
has that been an unexplored target in the past? 
An Empowered Patient Podcast Published November 14, 2025

 BULLISH!!! PART 3 Jay Lalezari: We have now been able to follow up on the 28 women who were enrolled in 
that study and have found that five of them are alive today, about five plus 
years later, three of whom have no evidence of disease. And these are women 
who were fourth-line median, fourth-line treatment median of two previous 
lines of treatment in the metastatic setting. 60% had organ metastasis, 30% had 
brain metastasis. The median survival of a population like that is generally 
measured in weeks or months. And the fact that we have five out of 28 who are 
alive and doing well in what appears to be a sustained remission five years later 
is absolutely remarkable. It is retrospective, but it is remarkable nonetheless. 
Karen Jagoda: Tell us a little bit about the CCR5 receptor, which is part of this story, and why 
has that been an unexplored target in the past? 
An Empowered Patient Podcast Published November 14, 2025

$CYDY BULLISH!!! PART 5 Jay Lalezari: Well, CCR5 emerged in the context of HIV, where it was found to be a secondary 
co-receptor for HIV entry. And for years, the development of leronlimab was 
focused on its potential role in the treatment of HIV. And indeed, leronlimab 
works as an antiviral. And over the years, leronlimab, I would add, has been 
given to almost 1600 patients, and we do not see a dominant safety signal or 
concern, which is just not something you can say about another cancer 
candidate therapeutic. 
Jay Lalezari: Over the years, it became clear that CCR5 was not just for the virus to get inside 
the cell, but was playing a key role in setting up the tumor microenvironment in 
a variety of solid tumors that were CCR5 positive. That included typically triple- 
negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, 
sarcoma, glioblastoma, and the urothelial cancers in particular.

 BULLISH!!! PART 5 Jay Lalezari: Well, CCR5 emerged in the context of HIV, where it was found to be a secondary 
co-receptor for HIV entry. And for years, the development of leronlimab was 
focused on its potential role in the treatment of HIV. And indeed, leronlimab 
works as an antiviral. And over the years, leronlimab, I would add, has been 
given to almost 1600 patients, and we do not see a dominant safety signal or 
concern, which is just not something you can say about another cancer 
candidate therapeutic. 
Jay Lalezari: Over the years, it became clear that CCR5 was not just for the virus to get inside 
the cell, but was playing a key role in setting up the tumor microenvironment in 
a variety of solid tumors that were CCR5 positive. That included typically triple- 
negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, 
sarcoma, glioblastoma, and the urothelial cancers in particular.

$CYDY BULLISH!!! PART 6 So CCR5 helps 
the cancer set up a tumor microenvironment that helps it both build blood 
vessels to provide nourishment for the cancer and attract suppressor cells that 
keep the host immune system at bay. 
Jay Lalezari: And by blocking that signaling through CCR5 with our antibody with leronlimab, 
we are breaking down that protective, suppressed immune environment and 
allowing the host immune system to now go after the virus. And what we found 
as the common denominator in these five women who received leronlimab was 
that they then had an induction of something called PDL-1 on their circulating 
tumor cells, which is an indication that the tumor has gone from cold to hot or 
from suppressed to inflamed.

 BULLISH!!! PART 6 So CCR5 helps 
the cancer set up a tumor microenvironment that helps it both build blood 
vessels to provide nourishment for the cancer and attract suppressor cells that 
keep the host immune system at bay. 
Jay Lalezari: And by blocking that signaling through CCR5 with our antibody with leronlimab, 
we are breaking down that protective, suppressed immune environment and 
allowing the host immune system to now go after the virus. And what we found 
as the common denominator in these five women who received leronlimab was 
that they then had an induction of something called PDL-1 on their circulating 
tumor cells, which is an indication that the tumor has gone from cold to hot or 
from suppressed to inflamed.

$CYDY BULLISH!!! PART 7  And then these five women were the ones who 
just happened to get an immune class of drugs called immune checkpoint 
inhibitors, PDL-1 or PDL-1 blockers, commonly known as Keytruda. So that was 
the magic formula that seemed to now correlate with their long-term sustained 
remission - that they received leromlimab, they induced PDL-1, they got a 
checkpoint inhibitor, and now they&#39;re alive today despite the long odds given 
their situation five years ago. 
Karen Jagoda: And it&#39;s really significant that what happens is that you turn the tumor from cold 
to hot. So, say a little bit more about the nature of cold tumors and how they&#39;re 
able to evade the immune system.

 BULLISH!!! PART 7  And then these five women were the ones who 
just happened to get an immune class of drugs called immune checkpoint 
inhibitors, PDL-1 or PDL-1 blockers, commonly known as Keytruda. So that was 
the magic formula that seemed to now correlate with their long-term sustained 
remission - that they received leromlimab, they induced PDL-1, they got a 
checkpoint inhibitor, and now they're alive today despite the long odds given 
their situation five years ago. 
Karen Jagoda: And it's really significant that what happens is that you turn the tumor from cold 
to hot. So, say a little bit more about the nature of cold tumors and how they're 
able to evade the immune system.

$CYDY BULLISH!!! PART 8 Jay Lalezari: Yes, that is absolutely correct, and it&#39;s the center of this. When a cancerous solid 
tumor sets out to grow, it has to do two things. It has to build blood vessels that 
specifically provide nourishment so that it can grow beyond a certain size. And 
then the tumor is a foreign antigen that the normally the immune system would 
attack and eliminate. Cancers have a variety of strategies for keeping the immune system at bay. It&#39;s 
just that some solid tumors use the CCR5 receptor on suppressor cells in tissue 
macrophages to recruit those cells to do the cancerous business for it. And so 
that cold tumor environment has blood vessels that feed the cancer, but has a 
collection of suppressor cells, both cells called regulatory T cells, for which the 
Nobel Prize in Medicine was just awarded a couple of weeks ago, and other 
suppressor cells to create a cold tumor environment that the immune system 
doesn&#39;t penetrate very well, if at all.

 BULLISH!!! PART 8 Jay Lalezari: Yes, that is absolutely correct, and it's the center of this. When a cancerous solid 
tumor sets out to grow, it has to do two things. It has to build blood vessels that 
specifically provide nourishment so that it can grow beyond a certain size. And 
then the tumor is a foreign antigen that the normally the immune system would 
attack and eliminate. Cancers have a variety of strategies for keeping the immune system at bay. It's 
just that some solid tumors use the CCR5 receptor on suppressor cells in tissue 
macrophages to recruit those cells to do the cancerous business for it. And so 
that cold tumor environment has blood vessels that feed the cancer, but has a 
collection of suppressor cells, both cells called regulatory T cells, for which the 
Nobel Prize in Medicine was just awarded a couple of weeks ago, and other 
suppressor cells to create a cold tumor environment that the immune system 
doesn't penetrate very well, if at all.

$CYDY BULLISH!!! PART 9 Jay Lalezari: And so that keeps the tumor from being recognized and destroyed. And so 
that&#39;s called a cold tumor microenvironment. And when you can break down 
that microenvironment and allow the cytotoxic T cells to enter the 
microenvironment and generate all these inflammatory cytokines, that&#39;s when tumor environment becomes hot. And one thing a cancer can do in response to 
an invading immune system is to generate this protein called PDL-1. 
Jay Lalezari: What PDL does is bind to an off switch on these attacking immune cells called 
BD-1, and by flipping that off switch, the tumor is able to downregulate or turn 
down or push back on the invading immune system. And so that&#39;s where the 
checkpoint inhibitor, Keytruda, comes in. And that is that the women who 
received leronlimab apparently had a breakdown in the tumor 
microenvironment, then secreted PDL-1 in an effort to repel the immune 
system.

 BULLISH!!! PART 9 Jay Lalezari: And so that keeps the tumor from being recognized and destroyed. And so 
that's called a cold tumor microenvironment. And when you can break down 
that microenvironment and allow the cytotoxic T cells to enter the 
microenvironment and generate all these inflammatory cytokines, that's when tumor environment becomes hot. And one thing a cancer can do in response to 
an invading immune system is to generate this protein called PDL-1. 
Jay Lalezari: What PDL does is bind to an off switch on these attacking immune cells called 
BD-1, and by flipping that off switch, the tumor is able to downregulate or turn 
down or push back on the invading immune system. And so that's where the 
checkpoint inhibitor, Keytruda, comes in. And that is that the women who 
received leronlimab apparently had a breakdown in the tumor 
microenvironment, then secreted PDL-1 in an effort to repel the immune 
system.

$CYDY BULLISH!!! PART 10  The women who just happened to get a checkpoint inhibitor to block 
the action of that protein, PDL-1, they&#39;re the ones who survived. 
Karen Jagoda: And the PDL-1 would not have worked otherwise, in terms of the 
immunotherapies. I mean, those people would be in the category where the 
immunotherapy just didn&#39;t work. Would that be fair to say? 
Jay Lalezari: That&#39;s exactly right. And so immunotherapy has been very successful, 
particularly in the last decade, but it&#39;s been successful in patients with solid 
tumors who express PDL-1. And unfortunately, it&#39;s the majority of solid tumors 
that don&#39;t. So the majority of solid tumors are cold. So for the patients whose 
cancers are PDL-1 positive, immunotherapy is hugely successful. GSK just got a 
breakthrough designation for their PDL-1 inhibitor, where their response rate 
was 100% in patients with rectal cancer who had hot tumors.

 BULLISH!!! PART 10  The women who just happened to get a checkpoint inhibitor to block 
the action of that protein, PDL-1, they're the ones who survived. 
Karen Jagoda: And the PDL-1 would not have worked otherwise, in terms of the 
immunotherapies. I mean, those people would be in the category where the 
immunotherapy just didn't work. Would that be fair to say? 
Jay Lalezari: That's exactly right. And so immunotherapy has been very successful, 
particularly in the last decade, but it's been successful in patients with solid 
tumors who express PDL-1. And unfortunately, it's the majority of solid tumors 
that don't. So the majority of solid tumors are cold. So for the patients whose 
cancers are PDL-1 positive, immunotherapy is hugely successful. GSK just got a 
breakthrough designation for their PDL-1 inhibitor, where their response rate 
was 100% in patients with rectal cancer who had hot tumors.

$CYDY BULLISH!!! PART 11 Jay Lalezari: So if we can cause cold tumors to go hot, we have a treatment that is highly 
successful. The trick is getting those cold tumors to turn hot. And that&#39;s where 
the excitement with leronlimab is that we saw that patients who got one of the 
two higher doses, both of which were well tolerated, 88% of those women had 
their tumors go from cold to hot over a period of one to two months. 
Karen Jagoda: That&#39;s really significant. And would this also be effective for colorectal cancer? 
Jay Lalezari: Yes, indeed. We started, we didn&#39;t know the full PDL-1 story, so we were 
working with the FDA and their requirements for how CytoDyn should move 
forward. And so the first study we designed was in colorectal cancer, looking at 
two doses, but it was all before we knew about the PDL-1 and checkpoint 
inhibitor story.

 BULLISH!!! PART 11 Jay Lalezari: So if we can cause cold tumors to go hot, we have a treatment that is highly 
successful. The trick is getting those cold tumors to turn hot. And that's where 
the excitement with leronlimab is that we saw that patients who got one of the 
two higher doses, both of which were well tolerated, 88% of those women had 
their tumors go from cold to hot over a period of one to two months. 
Karen Jagoda: That's really significant. And would this also be effective for colorectal cancer? 
Jay Lalezari: Yes, indeed. We started, we didn't know the full PDL-1 story, so we were 
working with the FDA and their requirements for how CytoDyn should move 
forward. And so the first study we designed was in colorectal cancer, looking at 
two doses, but it was all before we knew about the PDL-1 and checkpoint 
inhibitor story.

$CYDY BULLISH!!! I THINK I GOT IT ALL!!! THANKS FOR YOUR PATIENCE!!!

Thomas M.

 BULLISH!!! I THINK I GOT IT ALL!!! THANKS FOR YOUR PATIENCE!!!

@u2rocksme Phenomenal postings....THX 10% !!